Pristimerin Inhibits Breast Cancer Cell Migration by Up- Regulating Regulator of G Protein Signaling 4 Expression.

Xian-Min Mu,Wei Shi,Li-Xin Sun,Han Li,Yu-Rong Wang,Zhen-Zhou Jiang,Lu-Yong Zhang
DOI: https://doi.org/10.7314/apjcp.2012.13.4.1097
2012-01-01
Asian Pacific Journal of Cancer Prevention
Abstract:BACKGROUND/AIM:Pristimerin isolated from Celastrus and Maytenus spp can inhibit proteasome activity. However, whether pristimerin can modulate cancer metastasis is unknown.METHODS:The impacts of pristimerin on the purified and intracellular chymotrypsin proteasomal activity, the levels of regulator of G protein signaling 4 (RGS 4) expression and breast cancer cell lamellipodia formation, and the migration and invasion were determined by enzymatic, Western blot, immunofluorescent, and transwell assays, respectively.RESULTS:We found that pristimerin inhibited human chymotrypsin proteasomal activity in MDA-MB-231 cells in a dose-dependent manner. Pristimerin also inhibited breast cancer cell lamellipodia formation, migration, and invasion in vitro by up-regulating RGS4 expression. Thus, knockdown of RGS4 attenuated pristimerin-mediated inhibition of breast cancer cell migration and invasion. Furthermore, pristimerin inhibited growth and invasion of implanted breast tumors in mice.CONCLUSION:Pristmerin inhibits proteasomal activity and increases the levels of RGS4, inhibiting the migration and invasion of breast cancer cells.
What problem does this paper attempt to address?